Developer docs
API playgroundTry for free, no card

Search company profiles

Pharvaris

Full company profile

uuid0000ec5

Namestring
Pharvaris
Legal namestring
Pharvaris N.V.
Websiteurl
pharvaris.com
Company typeenum
Public
Founded yearint
2015
Descriptiontext

Pharvaris is a clinical-stage biopharmaceutical company developing oral bradykinin B2-receptor antagonists for the treatment and prevention of bradykinin-mediated angioedema attacks. The company's lead asset, deucrictibant, is being advanced in two distinct formulations: an immediate-release capsule (PHVS416) for on-demand treatment of acute hereditary angioedema (HAE) attacks, and an extended-release tablet (PHVS719) for once-daily prophylactic prevention of HAE attacks. The company is also pursuing the ultra-rare indication of acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH). Phase 3 RAPIDe-3 reported positive topline data in December 2025, with median time to symptom relief of 1.28 hours versus over 12 hours on placebo, a 92.8% End of Progression response rate versus 60.9% on placebo, and approximately 92% average reduction in attack rates observed in the CHAPTER-1 open-label extension for prophylaxis. An NDA submission for deucrictibant IR is planned for 1H2026, and the Phase 3 CHAPTER-3 prophylaxis study remains ongoing.

Pharvaris is incorporated in the Netherlands as Pharvaris N.V., with its principal operating entity, Pharvaris GmbH, located in Zug, Switzerland. The corporate structure also includes operating subsidiaries in Leiden, the Netherlands, and in Delaware, USA (Lexington, MA), where U.S. commercial activities are being built. The company is publicly listed on NASDAQ under the ticker PHVS and was founded in 2015 by Berndt Modig (current CEO), Anne Lesage (Chief Early Development Officer), Jochen Knolle, and Luc Dochez. Leadership has been deliberately constructed from executives with direct HAE drug development experience, including former senior roles at Jerini AG (originator of icatIbant/Firazyr), Takeda/Shire (TAKHZYRO), Genzyme, and Prosensa.

The business model is a pre-commercial biopharmaceutical model: the company generates no current revenue and recorded a €176 million net loss in 2025, financed entirely through equity capital. To date, Pharvaris has raised over $1 billion cumulatively, including a $70M private placement (June 2023), a $300M underwritten offering (December 2023), a $201.2M public offering (July 2025), a $175M public offering (April 2026), and two May 2026 offerings totaling $247.3M, with Morgan Stanley, Leerink Partners, Cantor, and Wells Fargo Securities acting as joint book-running managers on multiple transactions. The company held €292M in cash at the end of 2025 and €247M at Q1 2026, with runway extended into 2028. Upon regulatory approval, Pharvaris plans to commercialize through specialty pharmacy networks (e.g., Accredo, Orsini), specialty distributors, and direct outreach to allergy/immunology specialists and HAE treatment centers, targeting a global HAE patient population estimated at roughly 7,000-15,000 in the U.S., 9,000-15,000 in the EU, and 2,500-4,500 in Japan.

Short descriptiontext

Pharvaris is a clinical-stage biopharmaceutical company developing oral bradykinin B2-receptor antagonists (deucrictibant) for on-demand and prophylactic treatment of hereditary angioedema (HAE) and acquired angioedema, targeting a global rare-disease patient population.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersZug, Switzerland
HQ citystring
Zug
HQ countrystring
Switzerland
HQ regionstring
Europe
Markets served

Serves global market

Offices4 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
oral bradykinin antagonists, hereditary angioedema therapy, rare disease biopharmaceuticals, small molecule drug development, angioedema prophylaxis treatment
Industry3 codes
PRIMARYHLAIAIAG
Pulmonary Hypertension & Rare Pulmonary Disease Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAIALAB
Lead Optimization & Preclinical Candidate Selection
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYHLAIAHAF
Plasma-Derived Protease Inhibitors & Complement Modulators (e.g., C1 Esterase Inhibitor)
Product category
Rare Disease Therapeutics
Social media profiles3 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Pharmaceutical Product Sales (Projected)
TypeOne Time License
Description

Pre-revenue biopharmaceutical company with no current sales. Expected to generate revenue from commercialization of deucrictibant products for HAE and AAE-C1INH treatment once regulatory approvals are obtained. NDA submission for deucrictibant IR on-demand treatment planned for 1H2026.

simplywall.st
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Others
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 3 records shown
1Deucrictibant
Description

Novel, potent, oral small-molecule bradykinin B2 receptor antagonist for treatment and prevention of HAE attacks

pharvaris.com
+2 more records
Core offering1 text field

Pharvaris develops oral small-molecule bradykinin B2 receptor antagonists (deucrictibant) for the treatment and prevention of bradykinin-mediated angioedema attacks. The company's lead drug candidate is being advanced in two formulations: an immediate-release capsule (PHVS416) for on-demand treatment of acute hereditary angioedema (HAE) attacks and an extended-release tablet (PHVS719) for once-daily prophylactic prevention of HAE attacks.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 7 values shown
  • Median time to symptom relief of 1.28 hours vs. over 12 hours for placebo (Phase 3 RAPIDe-3)
+6 more records
Product overview1 text field

Pharvaris is developing deucrictibant, a novel oral bradykinin B2 receptor antagonist, in two distinct formulations: the immediate-release (IR) capsule (PHVS416) for on-demand treatment of acute HAE attacks, and the extended-release (XR) tablet (PHVS719) for prophylactic prevention of HAE attacks. Both formulations target the same underlying mechanism but are optimized for different treatment approaches—rapid onset for acute attacks versus sustained daily coverage for prevention.

Product and service2 records
1Deucrictibant Immediate-Release (IR) Capsule (PHVS416)
CategoryOn-demand HAE treatment
Description

Oral immediate-release capsule formulation of deucrictibant designed for on-demand treatment of acute hereditary angioedema (HAE) attacks, achieving therapeutic exposure within 15-30 minutes. Phase 3 RAPIDe-3 trial demonstrated median time to symptom relief of 1.28 hours versus over 12 hours for placebo.

2Deucrictibant Extended-Release (XR) Tablet (PHVS719)
CategoryProphylactic HAE treatment
Description

Oral extended-release tablet formulation of deucrictibant designed for once-daily prophylactic prevention of hereditary angioedema (HAE) attacks, maintaining sustained therapeutic exposure over 24 hours from day one. CHAPTER-1 open-label extension demonstrated approximately 92% average reduction in attack rates.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
1U.S. Hereditary Angioedema Association (HAEA)
Strategic tierCoreTypeOthers
Description

Pharvaris is committed to strong collaboration with the HAEA patient organization, working closely with the organization to support people living with HAE and their families through education, awareness, and research initiatives.

pharvaris.com
Strategic tierCoreTypeOthers
Description

Pharvaris supports HAE International's efforts to provide resources, education, and support to people living with HAE globally, collaborating on initiatives to amplify efforts and information to even more patients.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

BioCryst markets Orladeyo (berotralstat), the first FDA-approved oral prophylactic therapy for hereditary angioedema. As a direct competitor in the oral HAE space, it is the most relevant comparable for Pharvaris's deucrictibant franchise.

TypeDirect peer
Description

KalVista is developing sebetralstat, an oral on-demand HAE therapy in late-stage clinical trials. It is the closest direct head-to-head competitor to Pharvaris's PHVS416 on-demand program in mechanism, indication, and stage of development.

TypeBroad incumbent
Description

Takeda acquired Shire's HAE franchise (TAKHZYRO/lanadelumab, Cinryze, Firazyr) and is the market-leading player in HAE prophylaxis. Pharvaris's leadership includes the former global program lead for TAKHZYRO, making Takeda the dominant incumbent Pharvaris is positioning to displace.

TypeDirect peer
Description

Pharming markets Ruconest, a recombinant C1 esterase inhibitor for acute HAE attacks. It is a direct therapeutic-area peer competing for the same HAE on-demand patient population that deucrictibant PHVS416 targets.

TypeBroad incumbent
Description

CSL Behring markets Haegarda (subcutaneous C1-INH) and Berinert (C1-INH) for HAE prophylaxis and acute treatment. As a major rare-disease incumbent, it represents the plasma-derived C1-INH replacement standard against which Pharvaris's oral B2 antagonist must compete.

TypeBroad incumbent
Description

Sanofi Genzyme historically commercialized Firazyr (icatibant, a bradykinin B2 antagonist) for acute HAE attacks. Although Firazyr is now generic, Sanofi remains the originator of the B2-receptor antagonist class that deucrictibant builds upon.

TypeEmerging player
Description

Intellia is developing NTLA-2002, an in vivo CRISPR/Cas9 gene-editing therapy targeting kallikrein for HAE. It represents a potential future disruptive modality (one-time treatment) overlapping with Pharvaris's prophylactic and on-demand HAE programs.

TypeOthers
Description

Jerini AG originally developed icatibant (Firazyr), and several Pharvaris founders and executives came from Jerini/Prosensa. These heritage relationships are not active direct peers but underpin the comparable scientific lineage behind deucrictibant.

TypeBroad incumbent
Description

Regeneron develops antibody-based therapies for rare inflammatory and immunology indications. While not a direct HAE competitor today, it is a comparable late-stage clinical-to-commercial biopharma model with deep experience in specialty/rare-disease launches Pharvaris aims to replicate.

TypeBroad incumbent
Description

Vertex has built a profitable rare-disease specialty franchise through CFTR modulators and is expanding into other rare diseases. It serves as a relevant comparable for a late-stage small-molecule rare-disease company approaching first commercial launch.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles14 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries5 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds7 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors12 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Pharvaris

Rare Disease Therapeuticspharvaris.com

Pharvaris is a clinical-stage biopharmaceutical company developing oral bradykinin B2-receptor antagonists (deucrictibant) for on-demand and prophylactic treatment of hereditary angioedema (HAE) and acquired angioedema, targeting a global rare-disease patient population.

What Pharvaris does

Pharvaris is a clinical-stage biopharmaceutical company developing oral bradykinin B2-receptor antagonists for the treatment and prevention of bradykinin-mediated angioedema attacks. The company's lead asset, deucrictibant, is being advanced in two distinct formulations: an immediate-release capsule (PHVS416) for on-demand treatment of acute hereditary angioedema (HAE) attacks, and an extended-release tablet (PHVS719) for once-daily prophylactic prevention of HAE attacks. The company is also pursuing the ultra-rare indication of acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH). Phase 3 RAPIDe-3 reported positive topline data in December 2025, with median time to symptom relief of 1.28 hours versus over 12 hours on placebo, a 92.8% End of Progression response rate versus 60.9% on placebo, and approximately 92% average reduction in attack rates observed in the CHAPTER-1 open-label extension for prophylaxis. An NDA submission for deucrictibant IR is planned for 1H2026, and the Phase 3 CHAPTER-3 prophylaxis study remains ongoing.

Pharvaris is incorporated in the Netherlands as Pharvaris N.V., with its principal operating entity, Pharvaris GmbH, located in Zug, Switzerland. The corporate structure also includes operating subsidiaries in Leiden, the Netherlands, and in Delaware, USA (Lexington, MA), where U.S. commercial activities are being built. The company is publicly listed on NASDAQ under the ticker PHVS and was founded in 2015 by Berndt Modig (current CEO), Anne Lesage (Chief Early Development Officer), Jochen Knolle, and Luc Dochez. Leadership has been deliberately constructed from executives with direct HAE drug development experience, including former senior roles at Jerini AG (originator of icatIbant/Firazyr), Takeda/Shire (TAKHZYRO), Genzyme, and Prosensa.

The business model is a pre-commercial biopharmaceutical model: the company generates no current revenue and recorded a €176 million net loss in 2025, financed entirely through equity capital. To date, Pharvaris has raised over $1 billion cumulatively, including a $70M private placement (June 2023), a $300M underwritten offering (December 2023), a $201.2M public offering (July 2025), a $175M public offering (April 2026), and two May 2026 offerings totaling $247.3M, with Morgan Stanley, Leerink Partners, Cantor, and Wells Fargo Securities acting as joint book-running managers on multiple transactions. The company held €292M in cash at the end of 2025 and €247M at Q1 2026, with runway extended into 2028. Upon regulatory approval, Pharvaris plans to commercialize through specialty pharmacy networks (e.g., Accredo, Orsini), specialty distributors, and direct outreach to allergy/immunology specialists and HAE treatment centers, targeting a global HAE patient population estimated at roughly 7,000-15,000 in the U.S., 9,000-15,000 in the EU, and 2,500-4,500 in Japan.

Pharvaris firmographics

Firmographics
Name
Pharvaris
Legal name
Pharvaris N.V.
Website
https://pharvaris.com
Company type
Public
Founded year
2015
Operating status
Operating
Headcount range
101–250 employees
Short description
Pharvaris is a clinical-stage biopharmaceutical company developing oral bradykinin B2-receptor antagonists (deucrictibant) for on-demand and prophylactic treatment of hereditary angioedema (HAE) and acquired angioedema, targeting a global rare-disease patient population.
Ownership category
akta.pro rank

Pharvaris industry classification

Industry
Product category
Rare Disease Therapeutics
akta.pro industry
PRIMARYHLAIAIAG
Pulmonary Hypertension & Rare Pulmonary Disease Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAIALAB
Lead Optimization & Preclinical Candidate Selection
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYHLAIAHAF
Plasma-Derived Protease Inhibitors & Complement Modulators (e.g., C1 Esterase Inhibitor)

Keywords

  • Oral bradykinin antagonists
  • Hereditary angioedema therapy
  • Rare disease biopharmaceuticals
  • Small molecule drug development
  • Angioedema prophylaxis treatment

Where Pharvaris is headquartered

Location

Headquarters

HQ city
Zug
HQ country
Switzerland
HQ region
Europe

Offices4 records

Markets served

Pharvaris business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Revenue model

  1. Pharmaceutical Product Sales (Projected): Pre-revenue biopharmaceutical company with no current sales. Expected to generate revenue from commercialization of deucrictibant products for HAE and AAE-C1INH treatment once regulatory approvals are obtained. NDA submission for deucrictibant IR on-demand treatment planned for 1H2026.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels5 records

Pharvaris product offering

Product offering

Core offering

Pharvaris develops oral small-molecule bradykinin B2 receptor antagonists (deucrictibant) for the treatment and prevention of bradykinin-mediated angioedema attacks. The company's lead drug candidate is being advanced in two formulations: an immediate-release capsule (PHVS416) for on-demand treatment of acute hereditary angioedema (HAE) attacks and an extended-release tablet (PHVS719) for once-daily prophylactic prevention of HAE attacks.

Product overview

Pharvaris is developing deucrictibant, a novel oral bradykinin B2 receptor antagonist, in two distinct formulations: the immediate-release (IR) capsule (PHVS416) for on-demand treatment of acute HAE attacks, and the extended-release (XR) tablet (PHVS719) for prophylactic prevention of HAE attacks. Both formulations target the same underlying mechanism but are optimized for different treatment approaches—rapid onset for acute attacks versus sustained daily coverage for prevention.

Differentiator

Problem solved

Functional benefit

Brands

  • Deucrictibant: Novel, potent, oral small-molecule bradykinin B2 receptor antagonist for treatment and prevention of HAE attacks
  • PHVS416
  • PHVS719

Products and services

  • Deucrictibant Immediate-Release (IR) Capsule (PHVS416) Oral immediate-release capsule formulation of deucrictibant designed for on-demand treatment of acute hereditary angioedema (HAE) attacks, achieving therapeutic exposure within 15-30 minutes. Phase 3 RAPIDe-3 trial demonstrated median time to symptom relief of 1.28 hours versus over 12 hours for placebo.
  • Deucrictibant Extended-Release (XR) Tablet (PHVS719) Oral extended-release tablet formulation of deucrictibant designed for once-daily prophylactic prevention of hereditary angioedema (HAE) attacks, maintaining sustained therapeutic exposure over 24 hours from day one. CHAPTER-1 open-label extension demonstrated approximately 92% average reduction in attack rates.

Quantifiable outcome

  • Median time to symptom relief of 1.28 hours vs. over 12 hours for placebo (Phase 3 RAPIDe-3)
  • +6 more outcomes

Companies that use Pharvaris

Customer profile

Named customers1 record

Segments2 records

Ideal customer profiles2 records

Pharvaris technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Pharvaris partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core.

  • U.S. Hereditary Angioedema Association (HAEA)coreOthersPharvaris is committed to strong collaboration with the HAEA patient organization, working closely with the organization to support people living with HAE and their families through education, awareness, and research initiatives.
  • HAE International (HAEi)coreOthersPharvaris supports HAE International's efforts to provide resources, education, and support to people living with HAE globally, collaborating on initiatives to amplify efforts and information to even more patients.

Scale indicators7 records

Recent moves6 records

Expansion highlights6 records

Pharvaris competitors and assessment

Company assessment

Direct peers

  • BioCryst Pharmaceuticals: BioCryst markets Orladeyo (berotralstat), the first FDA-approved oral prophylactic therapy for hereditary angioedema. As a direct competitor in the oral HAE space, it is the most relevant comparable for Pharvaris's deucrictibant franchise.
  • KalVista Pharmaceuticals: KalVista is developing sebetralstat, an oral on-demand HAE therapy in late-stage clinical trials. It is the closest direct head-to-head competitor to Pharvaris's PHVS416 on-demand program in mechanism, indication, and stage of development.
  • Pharming Group: Pharming markets Ruconest, a recombinant C1 esterase inhibitor for acute HAE attacks. It is a direct therapeutic-area peer competing for the same HAE on-demand patient population that deucrictibant PHVS416 targets.

Broad incumbents

  • Takeda Pharmaceutical: Takeda acquired Shire's HAE franchise (TAKHZYRO/lanadelumab, Cinryze, Firazyr) and is the market-leading player in HAE prophylaxis. Pharvaris's leadership includes the former global program lead for TAKHZYRO, making Takeda the dominant incumbent Pharvaris is positioning to displace.
  • CSL Behring: CSL Behring markets Haegarda (subcutaneous C1-INH) and Berinert (C1-INH) for HAE prophylaxis and acute treatment. As a major rare-disease incumbent, it represents the plasma-derived C1-INH replacement standard against which Pharvaris's oral B2 antagonist must compete.
  • Sanofi: Sanofi Genzyme historically commercialized Firazyr (icatibant, a bradykinin B2 antagonist) for acute HAE attacks. Although Firazyr is now generic, Sanofi remains the originator of the B2-receptor antagonist class that deucrictibant builds upon.
  • Regeneron Pharmaceuticals: Regeneron develops antibody-based therapies for rare inflammatory and immunology indications. While not a direct HAE competitor today, it is a comparable late-stage clinical-to-commercial biopharma model with deep experience in specialty/rare-disease launches Pharvaris aims to replicate.
  • Vertex Pharmaceuticals: Vertex has built a profitable rare-disease specialty franchise through CFTR modulators and is expanding into other rare diseases. It serves as a relevant comparable for a late-stage small-molecule rare-disease company approaching first commercial launch.

Emerging players

  • Intellia Therapeutics: Intellia is developing NTLA-2002, an in vivo CRISPR/Cas9 gene-editing therapy targeting kallikrein for HAE. It represents a potential future disruptive modality (one-time treatment) overlapping with Pharvaris's prophylactic and on-demand HAE programs.

Others

  • Shire (now Takeda) / Jerini AG heritage companies: Jerini AG originally developed icatibant (Firazyr), and several Pharvaris founders and executives came from Jerini/Prosensa. These heritage relationships are not active direct peers but underpin the comparable scientific lineage behind deucrictibant.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

Pharvaris social profiles

Digital presence

Pharvaris financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Pharvaris leadership team

Management profile

Number of profiles

Profiles14 records

Pharvaris subsidiaries and ownership

Company hierarchy

Subsidiaries5 records

Pharvaris funding detail

Funding detail

Funding overview

Funding rounds7 records

Investors12 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Pharvaris M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Pharvaris

What does Pharvaris do?

Pharvaris develops oral small-molecule bradykinin B2 receptor antagonists (deucrictibant) for the treatment and prevention of bradykinin-mediated angioedema attacks. The company's lead drug candidate is being advanced in two formulations: an immediate-release capsule (PHVS416) for on-demand treatment of acute hereditary angioedema (HAE) attacks and an extended-release tablet (PHVS719) for once-daily prophylactic prevention of HAE attacks.

Is Pharvaris a public or private company?

Pharvaris is a public company. It is classified as public and is currently operating.

When was Pharvaris founded?

Pharvaris was founded in 2015. It employs 101 to 250 people.

Where is Pharvaris based?

Pharvaris is headquartered in Zug, Switzerland, in the Europe region.

How does Pharvaris make money?

One revenue line is on record: pharmaceutical Product Sales (Projected).

Who are Pharvaris's main competitors?

Direct peers on record are BioCryst Pharmaceuticals, KalVista Pharmaceuticals and Pharming Group. Broad incumbents are Takeda Pharmaceutical, CSL Behring, Sanofi, Regeneron Pharmaceuticals and Vertex Pharmaceuticals. Intellia Therapeutics is listed as an emerging player. Shire (now Takeda) / Jerini AG heritage companies is listed as an others.

Does Pharvaris have an API?

No public API is recorded for Pharvaris.

What industry is Pharvaris in?

Pharvaris's product category is Rare Disease Therapeutics. Its primary akta.pro industry code is HLAIAIAG, Pulmonary Hypertension & Rare Pulmonary Disease Therapies, with a secondary code of HLAIALAB, Lead Optimization & Preclinical Candidate Selection.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Business & FinancialPharvaris Presents Clinical And Real-World Data At The ACAAI 2026 Annual Scientific MeetingPharvaris presented Phase 3 CHAPTER-3 data at ACAAI 2026, showing deucrictibant XR reduced HAE attack rates by 83% overall and 87% in HAE Type 1 or 2. The drug was well tolerated with no treatment-related serious adverse events, and 45% of participants remained attack-free over 24 weeks.FinancialContent Business PagePharvaris Presents Clinical and Real-World Data at the ACAAI 2026 Annual Scientific MeetingPharvaris presented Phase 3 CHAPTER-3 results at ACAAI 2026, showing deucrictibant XR reduced HAE attack rates by 83% versus placebo. The drug was generally well tolerated with no treatment-related serious adverse events, and 45% of participants remained attack-free over 24 weeks.YahooPharvaris Presents Clinical and Real-World Data at the ACAAI 2026 Annual Scientific MeetingPharvaris presented Phase 3 CHAPTER-3 results at ACAAI 2026, showing deucrictibant XR reduced HAE attack rates by 83% versus placebo and 87% in HAE Type 1 or 2. The drug was generally well tolerated with no treatment-related serious adverse events, and 45% of participants remained attack-free over 24 weeks.Stock TitanPharvaris to present Phase 3 HAE data: attack rate 83% lowerPharvaris presented Phase 3 CHAPTER-3 data at ACAAI 2026, showing deucrictibant XR reduced HAE attack rates by 83% versus placebo across all types and 87% in HAE Type 1 or 2. The drug was generally well tolerated with no treatment-related serious adverse events.Business & FinancialPharvaris Reports Third Quarter 2026 Financial Results And Provides Business UpdatePharvaris reported Q3 2026 financial results, with a €47.4 million loss and €283 million in cash as of September 30, 2026. The company also provided a business update, including the FDA review of deucrictibant IR with a PDUFA date of April 23, 2027, and expected topline data from CREAATE part 1 in Q1 2027.FinancialContent Business PagePharvaris Reports Third Quarter 2026 Financial Results and Provides Business UpdatePharvaris reported Q3 2026 financial results, showing a €47.4 million loss and €283 million in cash as of September 30, 2026. The company highlighted successful readout of the deucrictibant XR Phase 3 study and ongoing CREAATE trial data expected in Q1 2027.TradingViewPharvaris Reports Third Quarter 2026 Financial Results and Provides Business UpdatePharvaris reported Q3 2026 financial results, with a €47.4 million loss and €283 million in cash as of September 30, 2026. The company highlighted the FDA review of deucrictibant IR's NDA with a PDUFA date of April 23, 2027, and expected topline data from CREAATE part 1 in Q1 2027.TradingViewPharvaris (PHVS) Reports Q3 Results After Phase 3 MilestonePharvaris reported Q3 2026 results and a successful Phase 3 readout for deucrictibant XR, with the FDA reviewing its NDA under a PDUFA date of April 23, 2027. The company holds €283 million in cash and is preparing for a potential first commercial launch, though no financial figures or launch date were disclosed.Stock TitanPharvaris Q3 earnings: loss widens to €47.4MPharvaris reported a Q3 2026 loss of €47.4M, up from €37.1M a year earlier, with R&D and G&A expenses rising. The company held €283M in cash as of September 30, 2026, and is preparing for a potential first commercial launch of deucrictibant.GlobeNewswirePharvaris Reports Third Quarter 2026 Financial Results and Provides Business UpdatePharvaris reported Q3 2026 results with a €47.4 million loss and €283 million in cash. The company highlighted the successful readout of deucrictibant XR's Phase 3 study and ongoing NDA preparation for submission in H1 2027.